Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects

Miguel Antonio Lasheras‐Pérez, Rodolfo David Palacios‐Diaz, Mónica Pozuelo‐Ruiz, Ignacio Torres‐Navarro, Rafael Botella‐Estrada, M. Rodríguez‐Serna

2023International Journal of Dermatology14 citationsDOI

Abstract

The data that support the findings of this study are available in PubMed: https://pubmed.ncbi.nlm.nih.gov/37098171/; https://pubmed.ncbi.nlm.nih.gov/37012527/; https://pubmed.ncbi.nlm.nih.gov/35980214/; https://pubmed.ncbi.nlm.nih.gov/36702810/; https://pubmed.ncbi.nlm.nih.gov/36660960/; https://pubmed.ncbi.nlm.nih.gov/36924265/; https://pubmed.ncbi.nlm.nih.gov/37017620/; https://pubmed.ncbi.nlm.nih.gov/37016961/; https://pubmed.ncbi.nlm.nih.gov/36404138/; https://pubmed.ncbi.nlm.nih.gov/37150301/; https://pubmed.ncbi.nlm.nih.gov/36794894/; https://pubmed.ncbi.nlm.nih.gov/36695072/.

Topics & Concepts

DupilumabMedicineAtopic dermatitisDermatologyDermatology and Skin DiseasesAsthma and respiratory diseasesUrticaria and Related Conditions